Gene transfer therapy in children with spinal muscular atrophy: A single‐center experience with a cohort of 25 children
Muscle & Nerve · 2023
DOI: 10.1002/mus.27926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2023. Verfasst von Nidheesh Chencheri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neurosciences Center of Excellence, Al Jalila Children's Specialty Hospital, Dubai, United Arab Emirates. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction/Aims New therapeutic strategies to increase survival motor neuron protein levels in spinal muscular atrophy (SMA) have focused on replacing the SMN1 gene. Onasemnogene abeparvovec was approved by the US Food and Drug Administration in 2019 for treatment of children with SMA less than 2 years of age. Postmarketing studies are limited, especially outside of Europe and the United States. Herein we describe a single‐center experience with onasemnogene abeparvovec from the Middle East.
Methods
Between November 17, 2020 and January 31, 2022, 25 children with SMA received onasemnogene abeparvovec at our center in the United Arab Emirates. Data were collected on patients’ demographics, age at diagnosis, SMA type, genetic information, relevant medical history, laboratory investigations, and Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP‐INTEND) functional assessment scores at baseline and 1 and 3 months after gene therapy.
Results
Onasemnogene abeparvovec was well tolerated. Significant improvements in CHOP‐INTEND scores were observed after the therapy. Elevation of liver enzymes and thrombocytopenia were the most common adverse events, but were transient and managed with high‐dose corticosteroids. There were no life‐threatening adverse events or deaths reported during the 3‐month follow‐up period.
Discussion
The study findings concurred with those of previously published studies. Side effects of gene transfer therapy are well tolerated, although serious complications can arise. In such cases, persistent transaminitis for example, steroid dose escalation is warranted with close observation of the patient's clinical status and lab values. Combination therapy should be explored as an alternative to gene transfer therapy only.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neurosciences Center of Excellence, Al Jalila Children's Specialty Hospital, Dubai, United Arab Emirates.
- Rehabilitation Department, Al Jalila Children's Specialty Hospital, Dubai, United Arab Emirates.
- Pediatric Department, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.
ORCID-Profile: Nidheesh Chencheri
Zitieren
APA
Chencheri, N., Alexander, G., Nugud, A., Majadas, E., Salim, H., Prudhomme, K., DeJager, N., Janardhanan, V. S., & Elbashir, H. (2023). Gene transfer therapy in children with spinal muscular atrophy: A single‐center experience with a cohort of 25 children. Muscle & Nerve. https://doi.org/10.1002/mus.27926
Vancouver
Chencheri N, Alexander G, Nugud A, Majadas E, Salim H, Prudhomme K, et al. Gene transfer therapy in children with spinal muscular atrophy: A single‐center experience with a cohort of 25 children. Muscle & Nerve. 2023. doi:10.1002/mus.27926
BibTeX
@article{Chencheri2023,
author = {Chencheri, Nidheesh and Alexander, Gail and Nugud, Ahmed and Majadas, Eurose and Salim, Haneen and Prudhomme, Katy and DeJager, Noleen and Janardhanan, Vaishnavi Shetty and Elbashir, Haitham},
title = {Gene transfer therapy in children with spinal muscular atrophy: A single‐center experience with a cohort of 25 children},
journal = {Muscle & Nerve},
year = {2023},
doi = {10.1002/mus.27926}
}
EUVIMED